Regeneron’s third-quarter revenue increased 36% to $5.116 billion, while GAAP diluted EPS rose to $18.45. The biotechnology company’s 30 October release reported non-GAAP diluted EPS of $20.07 for the same quarter.
A separate expansion of its Sanofi collaboration includes a $1 billion upfront payment to be recognized as collaboration revenue in the fourth quarter of 2026. It is not part of the Q3 revenue total.
Results and accounting basis
Q3 2026 | ended 30 September 2026. Amounts are US dollars unless stated otherwise. Primary source observed 2026-10-31T08:57:44.297Z.
| Measure or timetable | Verified figure and basis | Primary evidence |
|---|---|---|
| Q3 total revenue | $5.116bn; prior year $3.754bn; +36% | Regeneron official results |
| Q3 GAAP net income | $1.949bn, rounded; +33% | Regeneron official results |
| Q3 diluted EPS: GAAP / non-GAAP | $18.45 / $20.07 | Regeneron official results |
| Sanofi upfront collaboration payment | $1bn; recognition in Q4 2026 | Regeneron official results |
| Additional possible collaboration milestones | Up to $7bn; conditional future amounts | Regeneron official results |
| Dupixent global net sales in release | $6.5bn, recorded by Sanofi; not all Regeneron revenue | Regeneron official results |
Revenue and partner product sales are different
Regeneron’s release reported Dupixent global net sales of about $6.5 billion and expressly stated that those sales are recorded by Sanofi. They should not be added in full to Regeneron’s $5.116 billion revenue or described as another Regeneron revenue line.
GAAP net income was approximately $1.949 billion, while non-GAAP net income was $2.150 billion. The non-GAAP measures exclude specified items under Regeneron’s method. They provide supplementary information rather than a replacement for the reported accounts.
Do not book conditional milestones in advance
The expanded collaboration adds next-generation long-acting immunology antibodies. The issuer distinguishes the $1 billion upfront amount from the potential for up to a further $7 billion in future milestones. The latter is a maximum conditional opportunity, not an assured payment.
The timing is also material: the upfront amount is to be recognized in Q4, whereas the earnings table covers the three months ended 30 September. Comparing periods carefully avoids attributing third-quarter growth to a payment scheduled for accounting recognition later in the year.
What to watch
Watch Q4 recognition and future milestone conditions. Partner-recorded product sales, clinical progress and potential milestone amounts are not all Regeneron’s current revenue.
Primary source record
Regeneron Pharmaceuticals, Inc. — exact document: https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2026-financial-and-operating. Observed 2026-10-31T08:57:44.297Z. The issuer’s release is primary evidence for its own results, not independent corroboration.
Additional primary record
Regeneron Pharmaceuticals, Inc. — https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/regn-20260930.htm; checked 2026-10-31T09:06:13.080Z. Separate issuer quarterly Form 10-Q filed on SEC.gov; same issuer, not independent corroboration.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.